Increased circulating T cell reactivity to GM3 and GQ1b gangliosides in primary progressive multiple sclerosis

Journal of Clinical Neuroscience

Volumn 10, Issue 1, 2003, Pages 63-66

  Pender, Michael P ^a,b   Csurhes, Peter A ^a   Wolfe, Nigel P ^a,b   Hooper, Kaye D ^a,b   Good, Michael F ^c   McCombe, Pamela A ^a,b   Greer, Judith M ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Autoimmunity; Disease progression; Gangliosides; Multiple sclerosis; T lymphocytes

Indexed keywords

GANGLIOSIDE GD 1A; GANGLIOSIDE GD 1B; GANGLIOSIDE GD3; GANGLIOSIDE GM1; GANGLIOSIDE GM3; GANGLIOSIDE GQ 1B; GANGLIOSIDE GT 1B; MONOCLONAL ANTIBODY; SULFATIDE;

ARTICLE; AUTOIMMUNITY; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; HUMAN; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NERVE FIBER; PATHOGENESIS; PRIORITY JOURNAL; RELAPSE; REMISSION; T LYMPHOCYTE ACTIVATION;

EID: 0037212559     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0967-5868(02)00270-9     Document Type: Article

References (32)

1. Pender MP. Hypothesis: Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis. Lancet 1998; 351: 978-981.
2. Kracun I, Rosner H, Cosovic C, Stavljenic A. Topographical atlas of the gangliosides of the adult human brain. J Neurochem 1984; 43: 979-989.
3. Kusunoki S, Shimizu J, Chiba A, Ugawa Y, Hitoshi S, Kanazawa I. Experimental sensory neuropathy induced by sensitization with ganglioside GD1b. Ann Neurol 1996; 39: 424-431.
4. Arnon R, Crisp E, Kelley R, Ellison GW, Myers LW, Tourtellotte WW. Anti-ganglioside antibodies in multiple sclerosis. J Neurol Sci 1980; 46: 179-186.
5. M1. Ann Neurol 1980; 7: 587-590.
6. Endo T, Scott DD, Stewart SS, Kundu SK, Marcus DM. Antibodies to glycosphingolipids in patients with multiple sclerosis and SLE. J Immunol 1984; 132: 1793-1797.
7. Feix JB, Khatri B, McQuillen MP, Koethe SM. Immune reactivity against membranes containing ganglioside GM1 in chronic-progressive multiple sclerosis: Observation by spin-membrane immunoassay. Immunol Commun 1984; 13: 465-474.
8. Kasai N, Pachner AR, Yu RK. Anti-glycolipid antibodies and their immune complexes in multiple sclerosis. J Neurol Sci 1986; 75: 33-42.
9. Stevens A, Weller M, Wiethölter H. CSF and serum ganglioside antibody patterns in MS. Acta Neurol Scand 1992; 86: 485-489.
10. Bech E, Jakobsen J, Orntoft TF. ELISA-type titertray assay of IgM anti-GM1 autoantibodies. Clin Chem 1994; 40: 1331-1334.
11. Acarin N, Rio J et al. Different antiganglioside antibody pattern between relapsing-remitting and progressive multiple sclerosis. Acta Neurol Scand 1996; 93: 99-103.
12. Sadatipour BT, Greer JM, Pender MP. Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann Neurol 1998; 44: 980-983.
13. Mata S, Lolli F, Soderstrom M, Pinto F, Link H. Multiple sclerosis is associated with enhanced B cell responses to the ganglioside GD1a. Mult Scler 1999; 5: 379-388.
14. Offner H, Konat G. Stimulation of active E-rosette forming lymphocytes from multiple sclerosis patients by gangliosides and cerebrosides. J Neurol Sci 1980; 46: 101-104.
15. Offner H, Konat G, Sela BA. Multi-sialo brain gangliosides are powerful stimulators of active E-rosetting lymphocytes from multiple sclerosis patients. J Neurol Sci 1981; 52: 279-287.
16. Ilyas AA, Davison AN. Cellular hypersensitivity to gangliosides and myelin basic protein in multiple sclerosis. J Neurol Sci 1983; 59: 85-95.
17. Beraud E, Golstein MM et al. Multiple sclerosis: Cell-mediated immunity to human brain gangliosides. Autoimmunity 1990; 6: 13-21.
18. Shamshiev A, Donda A, Carena I, Mori L, Kappos L, De Libero G. Self glycolipids as T-cell autoantigens. Eur J Immunol 1999; 29: 1667-1675.
19. Poser CM, Paty DW et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983; 13: 227-231.
20. McDonald WI, Compston A et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50: 121-127.
21. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology 1996; 46: 907-911.
22. Pender MP. Multiple sclerosis. In: Pender Pender MP, McCombe PA (eds) Autoimmune Neurological Disease. Cambridge University Press, Cambridge 1995: 89-154.
23. Martin R, Bielekova B, Gran B, McFarland HF. Lessons from studies of antigen-specific T cell responses in multiple sclerosis. J Neural Transm Suppl 2000; 60: 361-373.
24. Greer JM, Csurhes PA, Cameron KD, McCombe PA, Good MF, Pender MP. Increased immunoreactivity to two overlapping peptides of myelin proteolipid protein in multiple sclerosis. Brain 1997; 120: 1447-1460.
25. Markovic-Plese S, Fukaura H et al. T cell recognition of immunodominant and cryptic proteolipid protein epitopes in humans. J Immunol 1995; 155: 982-992.
26. Greer JM, Sobel RA, Sette A, Southwood S, Lees MB, Kuchroo VK. Immunogenic and encephalitogenic epitope clusters of myelin proteolipid protein. J Immunol 1996; 156: 3719.
27. Pender MP, Csurhes PA et al. Surges of increased T cell reactivity to an encephalitogenic region of myelin proteolipid protein occur more often in patients with multiple sclerosis than in healthy subjects. J Immunol 2000; 165: 5322-5331.
28. Moody DB, Reinhold BB et al. Structural requirements for glycolipid antigen recognition by CD1b-restricted T cells. Science 1997; 278: 283-286.
29. Rees JH, Gregson NA, Hughes RA. Anti-ganglioside GM1 antibodies in Guillain-Barre syndrome and their relationship to Campylobacter jejuni infection. Ann Neurol 1995; 38: 809-816.
30. Baba H, Daune GC et al. Anti-GM1 ganglioside antibodies with differing fine specificities in patients with multifocal motor neuropathy. J Neuroimmunol 1989; 25: 143-150.
31. Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 1992; 31: 677-679.
32. Ho TW, Willison HJ et al. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barre syndrome. Ann Neurol 1999; 45: 168-173.